A bio-healthcare companyGENEWEL

With human-centered technology to open happy future for mankind

Genewel delivers future and happiness to the world.


Since its establishment in 2000, Genewel has established an unrivaled position in the domestic biomaterials field by developing and launching the best brand wound dressing material “Medifoam” and anti-adhesion agent “Guardix” based on its outstanding technology.

Currently, the company is conducting R&D in areas such as wound dressing, anti-adhesion agents, tissue restoration materials, chronic wound treatment materials, and functional drugs, and is also making efforts to expand its influence into various fields such as high-functional medical devices.

In order to achieve the best brand power in Korea as well as in the world, we are continuously discovering talents and performing social contribution, and doing our best to become a company that faithfully fulfills its roles and responsibilities through ethical management based on transparency and fairness.

In addition, through various industry-academy cooperation and national projects, we are pioneering new possibilities and values, and are focusing on R&D to become a leading company in the field of biomaterials and as well as a global bio company.

  • C.E.OSang-Deok Han
  • Established 0n 2000.7.21.
  • Major ProductsWound dressing, anti-adhesives
  • Main Phone +82-31-8018-5500
  • Business Sites
    • Main Office. 37 62-gil, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do
      (5/6th fl., STAR TOWER, Sangdaewon-dong)
    • Hwasung . 281-2, Soltaesangdu-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea
Financial Status

Balance Sheet Unit : million KRW

Genewel 2023year Financial Status Table
FY 2020Y FY 2021Y FY 2022Y
Total Assets 33,822 38,149 42,260
Current assets 12,586 24,094 26,157
Non-current assets 21,235 14,055 16,102
Total Liabilities 6,398 8,224 7,492
Current liabilities 3,974 6,632 6,754
Non-current liabilities 2,424 1,592 737
Total Assets 27,424 29,926 34,768

Income Statement Unit : million KRW

Genewel 2023year Income Statement
FY 2020Y FY 2021Y FY 2022Y
Revenue 25,899 30,321 32,496
Operating profit 7,235 7,885 9,279
Net profit 5,570 6,102 7,762